CompletedNCT00511940
Acamprosate or placebo for binge eating
About this title
Acamprosate in the Treatment of Binge-Eating Disorder
Read the official source — NCT00511940Medication studyAges 18–65United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- MasonSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00511940
- Official title
Show the full official title
Acamprosate in the Treatment of Binge-Eating Disorder
Get this study by email
Recruitment & locations
CompletedMason
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including acamprosate.
Who was this study for?
Listed age limits: 18 years to 65 years.
